RMTI Stock Overview
Rockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Rockwell Medical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.53 |
| 52 Week High | US$6.24 |
| 52 Week Low | US$1.16 |
| Beta | 1.2 |
| 1 Month Change | 8.93% |
| 3 Month Change | 3.04% |
| 1 Year Change | -26.33% |
| 3 Year Change | -84.79% |
| 5 Year Change | -96.99% |
| Change since IPO | -97.29% |
Recent News & Updates
Recent updates
Is Rockwell Medical (NASDAQ:RMTI) A Risky Investment?
Feb 06
Rockwell Medical, Inc. (NASDAQ:RMTI) Doing What It Can To Lift Shares
Dec 25Is Rockwell Medical (NASDAQ:RMTI) Using Too Much Debt?
Oct 11Is Rockwell Medical (NASDAQ:RMTI) Weighed On By Its Debt Load?
Jun 02Is There Now An Opportunity In Rockwell Medical, Inc. (NASDAQ:RMTI)?
Oct 25An Intrinsic Calculation For Rockwell Medical, Inc. (NASDAQ:RMTI) Suggests It's 46% Undervalued
Sep 02Rockwell Medical Q2 Earnings Preview
Aug 12Rockwell Medical: Triferic Remains Key Despite Sluggish Growth Profile
Mar 02Rockwell Medical: Down But By No Means Out
Oct 05Rockwell Medical pops 6% on licensing deal for Triferic AVNU in Turkey
Jun 08Health Check: How Prudently Does Rockwell Medical (NASDAQ:RMTI) Use Debt?
Mar 08Some Rockwell Medical, Inc. (NASDAQ:RMTI) Analysts Just Made A Major Cut To Next Year's Estimates
Feb 10How Many Rockwell Medical, Inc. (NASDAQ:RMTI) Shares Do Institutions Own?
Jan 18
Dosing underway in Rockwell Medical's late-stage Triferic trial in China
Jan 13Rockwell Medical: Heavily Oversold Company With Big Potential
Jan 11This Insider Has Just Sold Shares In Rockwell Medical, Inc. (NASDAQ:RMTI)
Dec 21Rockwell Medical, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 09Shareholder Returns
| RMTI | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -5.9% | -2.9% | -3.1% |
| 1Y | -26.3% | 2.1% | 20.9% |
Return vs Industry: RMTI underperformed the US Medical Equipment industry which returned 3.1% over the past year.
Return vs Market: RMTI underperformed the US Market which returned 22.4% over the past year.
Price Volatility
| RMTI volatility | |
|---|---|
| RMTI Average Weekly Movement | 10.4% |
| Medical Equipment Industry Average Movement | 7.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RMTI has not had significant price volatility in the past 3 months.
Volatility Over Time: RMTI's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 237 | Mark Strobeck | www.rockwellmed.com |
Rockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including testing supplies, 5% acetic acid cleaning solution, 5% and 2% citric acid descaler, filtration salts, and other items used by hemodialysis providers.
Rockwell Medical, Inc. Fundamentals Summary
| RMTI fundamental statistics | |
|---|---|
| Market cap | US$46.94m |
| Earnings (TTM) | -US$8.59m |
| Revenue (TTM) | US$83.61m |
0.5x
P/S Ratio-5.2x
P/E RatioIs RMTI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RMTI income statement (TTM) | |
|---|---|
| Revenue | US$83.61m |
| Cost of Revenue | US$74.91m |
| Gross Profit | US$8.70m |
| Other Expenses | US$17.29m |
| Earnings | -US$8.59m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.29 |
| Gross Margin | 10.41% |
| Net Profit Margin | -10.27% |
| Debt/Equity Ratio | 40.1% |
How did RMTI perform over the long term?
See historical performance and comparison